Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lorraine A Fitzpatrick

Showing results (31-40 of 67) with videos related to

Pageof 7
Sort By:
Seminars in Arthritis and Rheumatism|March 13, 2020
Cost-effectiveness of sequential treatment with abaloparatide followed by alendronate vs. alendronate monotherapy in women at increased risk of fracture: A US payer perspectiveMickael Hiligsmann, Setareh A Williams, Lorraine A Fitzpatrick, et al.
The Journal of Clinical Endocrinology and Metabolism|June 6, 2003
Prevalence and predictors of coronary artery calcification in women with polycystic ovary syndromeRose C Christian, Daniel A Dumesic, Thomas Behrenbeck, et al.
The Journal of Bone and Joint Surgery. American Volume|September 5, 2003
Barriers and solutions to osteoporosis care in patients with a hip fractureJohn D Kaufman, Mark E Bolander, Andrew D Bunta, et al.
Calcified Tissue International|June 29, 2018
Abaloparatide is an Effective Treatment Option for Postmenopausal Osteoporosis: Review of the Number Needed to Treat Compared with TeriparatideJean-Yves Reginster, Gary Hattersley, Gregory C Williams, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|November 5, 2011
Ronacaleret, a calcium-sensing receptor antagonist, increases trabecular but not cortical bone in postmenopausal womenLorraine A Fitzpatrick, Christine E Dabrowski, Gregory Cicconetti, et al.
Menopause (New York, N.Y.)|February 21, 2018
Effects of abaloparatide on bone mineral density and risk of fracture in postmenopausal women aged 80 years or older with osteoporosisMichael R McClung, Nicholas C Harvey, Lorraine A Fitzpatrick, et al.
Journal of Gastrointestinal Surgery : Official Journal of the Society for Surgery of the Alimentary Tract|October 26, 2002
Does bone change after biliopancreatic diversion?Picard Marceau, Simon Biron, Stéfane Lebel, et al.
The Anatomical Record. Part A, Discoveries in Molecular, Cellular, and Evolutionary Biology|May 13, 2003
Functional anatomy and hemodynamic characteristics of vasa vasorum in the walls of porcine coronary arteriesMario Gössl, Michael Rosol, Nasser M Malyar, et al.
Current Medical Research and Opinion|September 24, 2020
Abaloparatide: an anabolic treatment to reduce fracture risk in postmenopausal women with osteoporosisPaul D Miller, John P Bilezikian, Lorraine A Fitzpatrick, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|March 29, 2002
Rationale for the role of osteoclast-like cells in arterial calcificationTerence M Doherty, Hiroyasu Uzui, Lorraine A Fitzpatrick, et al.
Pageof 7

Showing results (31-40 of 67) with videos related to

Sort By:
Pageof 7
Seminars in Arthritis and Rheumatism|March 13, 2020
Cost-effectiveness of sequential treatment with abaloparatide followed by alendronate vs. alendronate monotherapy in women at increased risk of fracture: A US payer perspectiveMickael Hiligsmann, Setareh A Williams, Lorraine A Fitzpatrick, et al.
The Journal of Clinical Endocrinology and Metabolism|June 6, 2003
Prevalence and predictors of coronary artery calcification in women with polycystic ovary syndromeRose C Christian, Daniel A Dumesic, Thomas Behrenbeck, et al.
The Journal of Bone and Joint Surgery. American Volume|September 5, 2003
Barriers and solutions to osteoporosis care in patients with a hip fractureJohn D Kaufman, Mark E Bolander, Andrew D Bunta, et al.
Calcified Tissue International|June 29, 2018
Abaloparatide is an Effective Treatment Option for Postmenopausal Osteoporosis: Review of the Number Needed to Treat Compared with TeriparatideJean-Yves Reginster, Gary Hattersley, Gregory C Williams, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|November 5, 2011
Ronacaleret, a calcium-sensing receptor antagonist, increases trabecular but not cortical bone in postmenopausal womenLorraine A Fitzpatrick, Christine E Dabrowski, Gregory Cicconetti, et al.
Menopause (New York, N.Y.)|February 21, 2018
Effects of abaloparatide on bone mineral density and risk of fracture in postmenopausal women aged 80 years or older with osteoporosisMichael R McClung, Nicholas C Harvey, Lorraine A Fitzpatrick, et al.
Journal of Gastrointestinal Surgery : Official Journal of the Society for Surgery of the Alimentary Tract|October 26, 2002
Does bone change after biliopancreatic diversion?Picard Marceau, Simon Biron, Stéfane Lebel, et al.
The Anatomical Record. Part A, Discoveries in Molecular, Cellular, and Evolutionary Biology|May 13, 2003
Functional anatomy and hemodynamic characteristics of vasa vasorum in the walls of porcine coronary arteriesMario Gössl, Michael Rosol, Nasser M Malyar, et al.
Current Medical Research and Opinion|September 24, 2020
Abaloparatide: an anabolic treatment to reduce fracture risk in postmenopausal women with osteoporosisPaul D Miller, John P Bilezikian, Lorraine A Fitzpatrick, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|March 29, 2002
Rationale for the role of osteoclast-like cells in arterial calcificationTerence M Doherty, Hiroyasu Uzui, Lorraine A Fitzpatrick, et al.
Pageof 7